Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company developing novel gene therapies for rare, inherited metabolic conditions, announced its participation and presentations at the 30th European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress.

Vivet Therapeutics宣布将于2023年10月23日在法国巴黎举行的欧洲基因与细胞治疗学会（ESGCT）2023年会上发表演讲（GLOBE NEWSWIRE）-Vivet Therapeutics（“Vivet”），这是一家临床阶段生物技术公司，致力于开发针对罕见的遗传性代谢疾病的新型基因疗法，宣布参加第30届欧洲基因与细胞治疗学会（ESGCT）2023年会。

The congress will be held from October 24 – 27, 2023, in Brussels, Belgium. Dr. Nicholas Weber, Principal Scientist and Lead for New Programs and Innovations at Vivet, will present in an invited talk about adeno-associated virus (AAV) therapies targeting inherited cholestasis. Gloria Gonzalez-Aseguinolaza, Vivet Therapeutics Chief Scientific Officer, will also present new preclinical results related to its lead program VTX-801, which utilizes the proprietary recombinant AAV (rAAV) technology to target Wilson disease.

大会将于2023年10月24日至27日在比利时布鲁塞尔举行。Vivet的主要科学家兼新计划和创新负责人Nicholas Weber博士将在特邀演讲中介绍针对遗传性胆汁淤积的腺相关病毒（AAV）疗法。Vivet Therapeutics首席科学官Gloria Gonzalez Aseguinolaza还将介绍与其领导计划VTX-801相关的新临床前结果，该计划利用专有的重组AAV（rAAV）技术靶向Wilson病。

The presentation and poster details are listed below; the full program is available on the ESGCT website.Session 3c: Gene therapy for metabolic diseases at preclinical stageDate/Time: Wednesday 25 Oct at 8:30.Title: INV21 – Advances and pitfalls in AAV therapy targeting inherited cholestasisPresenter: Nicholas Weber, Ph.D , Principal Scientist, Vivet TherapeuticsRoom: Maison de la Poste, PARALLEL Poster Number: P035Category: AAV & non integrative vectorsPoster Title: Improvement of progressive familial intrahepatic cholestasis type 2 via AAV-mediated hepatic BSEP expression in mice Presenter: Angie Molina, Ph.D.

演示文稿和海报详细信息如下；完整的程序可在ESGCT网站上找到。会议3c：临床前阶段代谢性疾病的基因治疗/时间：10月25日星期三8:30。题目：INV21-针对遗传性胆汁淤积症的AAV治疗的进展和缺陷主持人：Nicholas Weber，博士，Vivet TherapeuticsRoom首席科学家：Maison de la Poste，平行海报编号：P035Category:AAV＆non-integrative vectorsPoster标题：通过AAV介导的小鼠肝脏BSEP表达改善2型进行性家族性肝内胆汁淤积症主持人：Angie Molina，Ph.D。

(Fundación para la Investigación Medica Aplicada in partnership with Vivet Therapeutics) Poster Number: P585Category: Metabolic DiseasesPoster Title: Therapeutic efficacy of VTX-801 Wilson’s disease mice a.

（FundaciónparaInvestigaciónMedica Aplicada与Vivet Therapeutics合作）海报编号：P585类别：代谢性疾病宿主标题：VTX-801 Wilson病小鼠的治疗效果a。